PROFProfound Medical Corp.
- GlobeNewswire
Profound Medical Reports Second Quarter 2026 Financial Results
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and ...
- GlobeNewswire
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative ...
- GlobeNewswire
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and ...
- GlobeNewswire
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; ...
- GlobeNewswire
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ...
- GlobeNewswire
Profound Medical Reports Strong First Quarter 2026 Financial Results
– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May ...
- PR Newswire
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical... ...
- GlobeNewswire
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a ...
- GlobeNewswire
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ...
- GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ...
- GlobeNewswire
Profound Medical Honored with INOVAIT's 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage innovator in interventional MRI ("iMRI") procedures, is pleased to announce ...
- GlobeNewswire
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health
TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Profound Medical Announces Upcoming Investor Events
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- GlobeNewswire
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for ...
- GlobeNewswire
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, ...
- Analyst Upgrades
Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12
Lake Street analyst Benjamin Haynor maintains Profound Medical with a Buy and raises the price target from $11 to $12. ...
- GlobeNewswire
Profound Medical Corp. Announces Closing of Private Placement
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has completed its previously announced private placement of common ...
- GlobeNewswire
Profound Medical Corp. Announces Upsize of Private Placement
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has increased the size of its private placement previously announced ...
- GlobeNewswire
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the closing of its previously announced registered direct offering of 5,142,870 ...
- GlobeNewswire
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a ...